Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.59 |
| ▸ | NR1I3 | Q14994 | 2/20 | 0.55 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.55 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.47 |
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2955007 | 1.00 | CYP19A1 (0.59) | CYP19A1NR1I3CDK5CDK5R1GRIN1 | |
| SCHEMBL10609022 | 0.81 | CDK5 (0.44) | CYP19A1NR1I3CDK5CDK5R1GRIN1 | |
| SCHEMBL3224692 | 0.80 | CDK5 (0.43) | CYP19A1NR1I3CDK5CDK5R1GRIN1 | |
| SCHEMBL10609234 | 0.80 | CDK5 (0.43) | CYP19A1NR1I3CDK5CDK5R1GRIN1 | |
| SCHEMBL10780071 | 0.80 | CDK5 (0.43) | CYP19A1NR1I3CDK5CDK5R1GRIN1 | |
| SCHEMBL11654859 | 0.80 | NR1I3 (0.46) | CYP19A1NR1I3CDK5CDK5R1GRIN1 | |
| SCHEMBL1319449 | 0.79 | NR1I3 (0.58) | CYP19A1NR1I3CDK5CDK5R1GRIN1 | |
| SCHEMBL1319450 | 0.79 | NR1I3 (0.58) | CYP19A1NR1I3CDK5CDK5R1GRIN1 | |
| SCHEMBL19733225 | 0.79 | NR1I3 (0.58) | CYP19A1NR1I3CDK5CDK5R1GRIN1 | |
| SCHEMBL10879635 | 0.79 | CYP19A1 (0.55) | CYP19A1NR1I3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220193095-A9 | PHARMACEUTICAL COMPOSITIONS | Shenzhen Pharmacin Co., Ltd. (CN) | 2022-06-23 | — | — | US | claimed |
| US-20220193095-A9 | PHARMACEUTICAL COMPOSITIONS | Shenzhen Pharmacin Co., Ltd. (CN) | 2022-06-23 | — | — | US | disclosed |
| US-20220133749-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | JANSSEN ONCOLOGY INC (US) | 2022-05-05 | — | — | US | disclosed |
| US-20070111973-A1 | TREATMENT OF TUMOURS | HAGSTROM TOMAS | 2007-05-17 | — | — | US | disclosed |
| US-20050192262-A1 | Treatment of tumours | HAGSTROM, TOMAS (SE) | 2005-09-01 | — | — | US | disclosed |
| EP-1379542-A2 | TREATMENT OF TUMOURS | Hagström, Tomas (SE) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002072003-A2 | USE OF STEROID DERIVATIVES FOR THE TREATMENT OF A BENIGHN AND/OR MALIGNANT TUMOUR | HAGSTROEM TOMAS (SE) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192262-A1 | Treatment of tumours | SULT2A1, SULT1A1, HSD17B11 | CYP19A1 20/4885NR1I3 134/4885CDK5 238/4885 |
| US-20220193095-A9 | PHARMACEUTICAL COMPOSITIONS | LIPA, LIPC, MGLL | CYP19A1 674/4885NR1I3 3198/4885CDK5 4709/4885 |
| US-20220133749-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CYP17A1, HSD17B7, HSD17B11 | CYP19A1 17/4885NR1I3 600/4885CDK5 291/4885 |
| US-20070111973-A1 | TREATMENT OF TUMOURS | SULT2A1, SULT1A1, SULT1E1 | CYP19A1 24/4885NR1I3 139/4885CDK5 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.